Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-024447
Filing Date
2022-11-10
Accepted
2022-11-10 16:06:56
Documents
71
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q glue-20220930.htm   iXBRL 10-Q 2552354
2 EX-31.1 glue-ex31_1.htm EX-31.1 21201
3 EX-31.2 glue-ex31_2.htm EX-31.2 21185
4 EX-32.1 glue-ex32_1.htm EX-32.1 20612
  Complete submission text file 0000950170-22-024447.txt   8006055

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT glue-20220930_cal.xml EX-101.CAL 42622
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT glue-20220930_pre.xml EX-101.PRE 336280
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT glue-20220930.xsd EX-101.SCH 49711
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT glue-20220930_def.xml EX-101.DEF 174025
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT glue-20220930_lab.xml EX-101.LAB 429913
65 EXTRACTED XBRL INSTANCE DOCUMENT glue-20220930_htm.xml XML 1293900
Mailing Address 645 SUMMER STREET SUITE 102 BOSTON MA 02210
Business Address 645 SUMMER STREET SUITE 102 BOSTON MA 02210 617-949-2643
Monte Rosa Therapeutics, Inc. (Filer) CIK: 0001826457 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40522 | Film No.: 221377093
SIC: 2836 Biological Products, (No Diagnostic Substances)